GEMSTONE-302 trail (4, 6) revealed that, compared to placebo plus chemotherapy (PC), the sugemalimab plus chemotherapy (SC) remarkably extended the median overall survival (mOS) by 8.5 months (mOS, 25.4 vs. 16.9 months; hazard ratio (HR), 0.65; 95% CI, 0.50–0.84) and prolonged median progression-free survival (mPFS) by 4.1 months (mPFS, 9.0 vs. 4.9 months; HR, 0.48; 95% CI, 0.39–0.60) for patients with NSCLC, regardless of PD-L1 expression level and tumor pathological type. This evidence concerns the gene CD274 and neoplasm.